BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot, given the previous late-stage failures of both agents in Alzheimer’s trials. Perhaps more surprising is that both compounds remain...
BioCentury | Oct 30, 2019
Company News

Amgen narrows neuro focus to inflammation

Despite early success for Amgen’s first marketed neurology product, the company will exit research and early development for neuroscience, narrowing its focus to neuroinflammation. “To compete effectively, we need to make investments in the areas...
BioCentury | Oct 1, 2019
Company News

Biogen turns to R&D vet as Ehlers exits

While Biogen head of R&D Michael Ehlers is departing the biotech to join the VC ranks amid a series of recent clinical disappointments, pipeline additions during his tenure could start to bear fruit over the...
BioCentury | Sep 14, 2019
Clinical News

One amyloid candidate left for Biogen, Eisai after axing BACE trials

Despite ending two Phase III trials of BACE inhibitor elenbecestat Friday, Biogen and Eisai have not walked away from the amyloid hypothesis of Alzheimer’s disease. The partners' Phase III trial of anti-amyloid mAb BAN2401 forges...
BioCentury | Jul 12, 2019
Clinical News

Amyloid hypothesis takes first hit in an Alzheimer’s prevention setting

With Novartis and Amgen’s decision to halt a pair of trials in presymptomatic Alzheimer’s patients Thursday, what was widely considered the only setting left for the amyloid hypothesis in the disease took a blow. Amyloid-lowering...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | May 10, 2019
Financial News

New Eisai venture arm to focus on digital tech, dementia, cancer

As Eisai looks to digital technologies for dementia drug discovery, the Japanese pharma’s newly launched venture arm has made its first investment and backed Tokyo-based digital healthcare company Allm. Eisai Co. Ltd. (Tokyo:4523) said the...
BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
Items per page:
1 - 10 of 196